Latest Posts - Disruptive Tech Research

PRVB: Q3 2022 Update & Outlook

by Lou Basenese | Oct 13, 2022 | PRVB

Full rundown on Provention Bio (PRVB) as the Q3 2022 quarterly call and November 17 PDUFA dates approach…

by Lou Basenese | Jun 15, 2022 | Webinar

A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.

by Lou Basenese | May 2, 2022 | ATOM

Key takeaways from the latest quarterly report from Atomera Inc. (ATOM), including the possible identity of the latest “major” foundry customer…

by Lou Basenese | Apr 27, 2022 | IMNM

Low float stocks are prone to major moves on nominal volume. Unfortunately in both directions. Here’s what’s going on with IMNM…

by Lou Basenese | Feb 21, 2022 | CUE

In this 1.5 hour webinar, Dr. D.J. Verret shares his unique clinical perspective on Cue Biopharma’s (CUE) approach and latest data

by Lou Basenese | Feb 16, 2022 | ATOM

Per your feedback, here’s my quick take on Atomera’s fourth quarter report…

by Lou Basenese | Feb 15, 2022 | RESN

Resonant Inc. (RESN) announced it’s being acquired for $4.50 per share by long-term strategic partner, Murata

by Lou Basenese | Jan 27, 2022 | CUE

Here’s a full rundown on the important takeaways from CUE’s conference call and my thoughts on the recent trading activity…

by Lou Basenese | Jan 26, 2022 | CUE

Like expectant parents, everyone’s wondering what will be revealed on today’s update call. Here are my reasonable expectations…

by Lou Basenese | Jan 20, 2022 | Webinar

A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.